Tranexamic acid for reduction of blood loss after Caesarean delivery: a cost-effectiveness analysis of the TRAAP2 trial
Primary result · Mean total costs until occurrence of a complication of interestResult — go to the resultDifference 55 €Authors' conclusion
Tranexamic acid for the prevention of blood loss is cost-effective in reducing complications after Caesarean delivery at day 90 postpartum. However, the effect size (in cost and effectiveness) is very low.
Study context
- Population
- Women having a Caesarean delivery before or during labour at ≥34 weeks of gestation, 27 French maternity hospitals, 2018–2020
- Comparison
- Tranexamic acid vs placebo at Caesarean delivery
- Primary endpoint
- Cost of hospital stay for delivery and incremental cost per delivery without complication within 90 days after delivery
- Follow-up
- 90 days
Methodological detailsmulticentre, double-blinded
- Multicentre
- Double-blinded
Primary result
As reported in the abstract
Mean total costs until occurrence of a complication of interest
Difference
55 €
By group
- Adjusted incremental cost-effectiveness ratio per additional Caesarean delivery without a complication at 90 days
- €762
- Cost-effectiveness probability of tranexamic acid vs placebo at a threshold of €10,000
- 99.9%
- Cost-effectiveness probability for thresholds from €0 to €10,000 per additional delivery without a complication at day 90
- 5.8% to 100.0%
Further findings
Women without complications · day 90
Original publication
Tranexamic acid for reduction of blood loss after Caesarean delivery: a cost-effectiveness analysis of the TRAAP2 trial. Br J Anaesth. Published 9 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →